Sage Therapeutics to Present at 2019 RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass--(BUSINESS WIRE)--May 14, 2019--
Sage Therapeutics (NASDAQ:SAGE), a biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that the Company will present at the 2019 RBC Capital Markets Global Healthcare Conference on Tuesday, May 21, 2019 at 3:35 p.m. EDT in New York, NY.
A live webcast of the presentation can be accessed on the investor page of Sage’s website at investor.sagerx.com. A replay of the webcast will also be archived for up to 30 days on Sage’s website following the conference.
About Sage Therapeutics
Sage Therapeutics is a biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage’s portfolio of novel compounds targets critical receptor systems in the brain and includes the first treatment specifically approved by the U.S. Food and Drug Administration for postpartum depression as well as compounds being developed as potential treatments for diseases such as major depressive disorder, insomnia, bipolar disorder and essential tremor. For more information, please visit www.sagerx.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190514005202/en/
CONTACT: Investor Contact:
Maren Killackey, 617-949-4113
Jeff Boyle, 617-949-4256
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Sage Therapeutics
Copyright Business Wire 2019.
PUB: 05/14/2019 06:30 AM/DISC: 05/14/2019 06:30 AM